VX A901
Alternative Names: VX-A901Latest Information Update: 22 Jul 2024
At a glance
- Originator VERAXA Biotech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
Most Recent Events
- 16 Jul 2024 Efficacy and adverse events data from a phase-I trial in acute myeloid leukemia released by VERAXA Biotech (VERAXA Biotech pipeline; July 2024).
- 08 Jul 2024 Phase-I clinical trials in Acute myeloid leukaemia (In the eldrly, Second-line therapy or greater) (Parenteral) (VERAXA Biotech pipeline; July 2024)